THE ROLE OF COMBINATION IMMUNE CHECKPOINT INHIBITORS AS SALVAGE THERAPY FOR PD-1/PD-L1RESISTANT MERKEL CELL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
ACTIVITY OF THE TUMOR-INTRINSIC NLRP3 INFLAMMASOME PATHWAY PREDICTS FOR RESPONSE TO CHECKPOINT INHIBITOR IMMUNOTHERAPY IN MELANOMA PATIENTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection未完成淋巴结清扫的前哨淋巴结阳性黑色素瘤患者的辅助anti-PD-1治疗结果JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-08-246OAAI
CHARACTERIZATION AND THERAPEUTIC TARGETING OF A TUMOR-ASSOCIATED TOLEROGENIC DC SUBPOPULATION DRIVEN BY SREBP2 AND THE MEVALONATE METABOLIC PATHWAYJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
INVESTIGATION OF WNT LIGAND SIGNALING REGULATORS AS A PREDICTOR OF ANTI-PD-1 RESPONSE IN METASTATIC MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
A PHASE I TRIAL OF INTRATUMORAL PVSRIPO IN PATIENTS WITH UNRESECTABLE TREATMENT REFRACTORY MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向